Rosa Bacchetta
Associate Professor (Research) of Pediatrics (Stem Cell Transplantation)
Pediatrics - Stem Cell Transplantation
NIH Biosketch available Online

CONTACT INFORMATION
- Administrative Assistant
  Michelle Narayan

  Email  michelle.narayan@stanford.edu
  Tel (650) 725-9250

Bio

My professional goal as a pediatrician specializing in immunology, has been to challenge the limits of "inexplicable" and "untreatable" diseases, and apply current scientific knowledge to understand the mechanisms of impaired cellular immune function underlying the clinical manifestations in order to develop curative treatments.

Following the completion of my pediatrics residency, I received training in molecular and cellular immunology in France (UNICET, Lyon) and the United States (DNAX Research Institute of Molecular and Cellular Biology, Palo Alto) under scientists, who critically influenced my scientific development. There, I was first exposed to the importance of integrating in depth laboratory research with clinical observations to develop a translational research approach to science. I then worked for fifteen years at the San Raffaele Scientific Institute in the Telethon Institute for Gene Therapy (HSR-TIGET), where I focused on dissecting the genetic and immunological basis of primary immunodeficiencies with autoimmune manifestations that might be treated by gene therapy.

ACADEMIC APPOINTMENTS
- Associate Professor (Research), Pediatrics - Stem Cell Transplantation
- Member, Bio-X
- Member, SPARK at Stanford
- Member, Maternal & Child Health Research Institute (MCHRI)

HONORS AND AWARDS
- Associate Professor in Pediatrics, Italian Ministry of University (01/2014)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS
- Member, European Society of Immunodeficiency (ESID) (2014 - present)
- Member, Federal of Clinical Immunology Societies (FOCIS and CIS) (2014 - present)
- Associate Editor, Frontiers in Primary Immunodeficiencies (2014 - present)
- Reviewer, J Medical Genetics (2014 - present)
- Reviewer, J Autoimmunity (2014 - present)
• Reviewer, J Endocrinology (2014 - present)
• Reviewer, European Journal of Immunology (2014 - present)
• Reviewer, Transplantation (2014 - present)
• Grants revisions, European Research Council (2014 - present)
• Grants revisions, INSERM (2014 - present)
• Grants revision, LSBR Foundation (2014 - present)
• Grants revision, Wellcome Trust (2014 - present)
• Grants revision, ANR-France (2014 - present)
• Teaching activities ad Hoc lessons, Vita-Salute University Medical School and Biotechnology, Milan (2014 - present)
• Teaching activities ad hoc lessons, Tor Vergata University, Rome (2014 - present)
• Teaching activities ad hoc lessons, Undergraduate Course at Stanford University, Stanford, Palo Alto, CA (2014 - present)

PROFESSIONAL EDUCATION
• Fellowship, University of Turin, Italy, General Pediatrics Immunology (1991)
• MD, University of Turin, Italy, Medicine (1987)

PATENTS
• Rosa Bacchetta. "United States Patent WO2007/131575 Tr1 dendritic cells, method to generate regulatory type 1 T (Tr1) cells and uses thereof", Rosa Bacchetta, Apr 1, 2007
• Rosa Bacchetta. "United States Patent 6884410 Methods for modulating antigen-specific immune responses", Rosa Bacchetta, Apr 26, 2005
• Rosa Bacchetta. "United States Patent 6277635 Use of Interleukin-10 produce a population of suppressor cells", Rosa Bacchetta, Aug 21, 2001

LINKS
• Division of Stem Cell Transplantation and Regenerative Medicine: http://med.stanford.edu/ptrm.html
• Bacchetta Lab: http://med.stanford.edu/bacchettalab.html

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS
In the coming years, I plan to further determine the genetic and immunological basis of diseases with autoimmunity or immune dysregulation in children. I believe that much can still be learned from the in depth mechanistic studies of pediatric autoimmune diseases. Genomic analysis of the patients' samples has become possible which may provide a rapid indication of altered target molecules. I plan to implement robust functional studies to define the consequences of these genetic abnormalities and bridge them to the patient's clinical phenotype.

Understanding functional consequences of gene mutations in single case/family first and then validating the molecular and cellular defects in other patients with similar phenotypes, will anticipate and complement cellular and gene therapy strategies.

For further information please visit the Bacchetta Lab website:
http://med.stanford.edu/bacchettalab.html

CLINICAL TRIALS
• CD4^LVFOXP3 in Participants With IPEX, Not Recruiting
• Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Adults With T-allo10 Cells Addback, Not Recruiting
Teaching

STANFORD ADVISEES
Postdoctoral Faculty Sponsor
Simon Borna

GRADUATE AND FELLOWSHIP PROGRAM AFFILIATIONS
- Immunology (Phd Program)
- Pediatric Hem/Onc (Fellowship Program)
- Stem Cell Biology and Regenerative Medicine (Phd Program)

Publications

PUBLICATIONS

- Preclinical Safety and Efficacy Validation of CD4(LVFOXP3) Cells as an Innovative Cell-Based Gene Therapy Approach for IPEX Syndrome
  Sato, Y., Nathan, A., Wright, J., Tate, K., Wani, P., Fazeli, F., Timnak, A., Bhatia, N., Agarwal-Hashmi, R., Bertaina, A., Roncarolo, M., Bacchetta, R.
  CELL PRESS. 2021: 340

- Thymic origins of autoimmunity-lessons from inborn errors of immunity. *Seminars in immunopathology*
  Bacchetta, R., Weinberg, K.
  2021

- CRISPR-based gene editing enables FOXP3 gene repair in IPEX patient cells *SCIENCE ADVANCES*
  Goodwin, M., Lee, E., Lakshmanan, U., Shipp, S., Froessl, L., Barzaghi, F., Passerini, L., Narula, M., Sheikali, A., Lee, C. M., Bao, G., Bauer, C. S., Miller, et al
  2020; 6 (19)

- Engineered Type-1 Regulatory T Cells as Cellular Therapy for Treatment of Immune Mediated Diseases
  Liu, J. M., Chen, P., Cieniewicz, B., Cepika, A., Bacchetta, R., Roncarolo, M.
  AMER ASSOC IMMUNOLOGISTS. 2020

- Regulatory Type 1 T Cell Infusion in Mismatched Related or Unrelated Hematopoietic Stem Cell Transplantation (HSCT) for Hematologic Malignancies
  Agarwal, R., Bacchetta, R., Bertaina, A., Chen, P., Saini, G., Shiraz, P., Bhatia, N., Roncarolo, M.
  ELSEVIER SCIENCE INC. 2020: S272–S273

- Human inborn errors of immunity: An expanding universe. *Science immunology*
  Notarangelo, L. D., Bacchetta, R. n., Casanova, J. L., Su, H. C.
  2020; 5 (49)

- Hematopoietic Cell Transplantation in Patients With Primary Immune Regulatory Disorders (PIRD): A Primary Immune Deficiency Treatment Consortium (PIDTC) Survey. *Frontiers in immunology*
  Chan, A. Y., Leiding, J. W., Liu, X., Logan, B. R., Burroughs, L. M., Allenspach, E. J., Skoda-Smith, S., Uzel, G., Notarangelo, L. D., Slatter, M., Gennery, A. R., Smith, A. R., Pai, et al
  2020; 11: 239

- Human-engineered Treg-like cells suppress FOXP3-deficient T cells but preserve adaptive immune responses in vivo. *Clinical & translational immunology*
  Sato, Y. n., Passerini, L. n., Piening, B. D., Uyeda, M. J., Goodwin, M. n., Gregori, S. n., Snyder, M. P., Bertaina, A. n., Roncarolo, M. G., Bacchetta, R. n.
  2020; 9 (11): e1214

- The autoimmune targets in IPEX are dominated by gut epithelial proteins *JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY*
  Eriksson, D., Bacchetta, R., Gunnarsson, H., Chan, A., Barzaghi, F., Ehl, S., Hallgren, A., van Gool, F., Sardh, F., Lundqvist, C., Laakso, S. M., Ronnhblom, A., Ekwall, et al
  2019; 144 (1): 327+

- Immunoregulatory Cell Therapy with Lentiviral-Mediated FOXP3 Converted CD4+T Cells into Treg Cells: Towards the Proof-of-Concept Application in IPEX Syndrome
  Sato, Y., Passerini, L., Roncarolo, M., Bacchetta, R.
Case Study: Mechanism for Increased Follicular Helper T Cell Development in Activated PI3K Delta Syndrome. *Frontiers in immunology*
Thauland, T. J., Pellerin, L., Oghami, R. S., Bacchetta, R., Butte, M. J.
2019; 10: 753

Epigenetic Immune Cell Quantification for Diagnosis and Monitoring of Patients with Primary Immune Deficiencies and Immune Regulatory Disorders
Schulze, J., Werner, J., Schildknecht, K., Lakshmanan, U., Gruetzkau, A., Chu, J., Gernez, Y., Speckmann, C., Weinacht, K. G., Bertaina, A., Baron, U., Borte, S., Olek, et al
*SPRINGER/PLENUM PUBLISHERS*.2019: S30

Treatment with Rapamycin Can Restore Regulatory T Cell Function in IPEX Patients. *The Journal of allergy and clinical immunology*
Passerini, L. n., Barzaghi, F. n., Curto, R. n., Sartirana, C. n., Barera, G. n., Tucci, F. n., Albarello, L. n., Mariani, A. n., AlbertoTestoni, P. n., Bazzigaluppi, E. n., Bosi, E. n., Lampasona, V. n., Neth, et al
2019

Tregopathies: Monogenic diseases resulting in regulatory T-cell deficiency. *The Journal of allergy and clinical immunology*
Cepika, A., Sato, Y., Liu, J. M., Uyeda, M. J., Bacchetta, R., Roncarolo, M. G.
2018; 142 (6): 1679–95

Epigenetic immune cell counting in human blood samples for immunodiagnoistics *SCIENCE TRANSLATIONAL MEDICINE*
Baron, U., Werner, J., Schildknecht, K., Schulze, J. J., Mulu, A., Liebert, U., Sack, U., Speckmann, C., Gossen, M., Wong, R. J., Stevenson, D. K., Babel, N., Schuermann, et al
2018; 10 (452)

Reprogramming human T cell function and specificity with non-viral genome targeting *NATURE*
Roth, T. L., Puig-Saus, C., Yu, R., Shifrut, E., Carnevale, J., Li, P., Hiatt, J., Saco, J., Krystofinski, P., Li, H., Tobin, V., Nguyen, D. N., Lee, et al
2018; 559 (7714): 405-+

Neutralizing Anti-Cytokine Autoantibodies Against Interferon-alpha in Immunodysregulation Polyendocrinopathy Enteropathy X-Linked *FRONTIERS IN IMMUNOLOGY*
Rosenberg, J. M., Maccari, M. E., Barzaghi, F., Allenspach, E. J., Pignata, C., Weber, G., Torgerson, T. R., Utz, P. J., Bacchetta, R.
2018; 9: 544

Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study *JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY*
Barzaghi, F., Hernandez, L., Neven, B., Ricci, S., Kucuk, Z., Bleesing, J. J., Nademi, Z., Slatter, M., Ulloa, E., Shcherbina, A., Roppelt, A., Worth, A., Silva, et al
2018; 141 (3): 1036-+

Forkhead-Box-P3 Gene Transfer in Human CD4(+) T Conventional Cells for the Generation of Stable and Efficient Regulatory T Cells, Suitable for Immune Modulatory Therapy *FRONTIERS IN IMMUNOLOGY*
Passerini, L., Bacchetta, R.
2017; 8: 1282

From IPEX syndrome to FOXP3 mutation: a lesson on immune dysregulation. *Annals of the New York Academy of Sciences*
Bacchetta, R., Barzaghi, F., Roncarolo, M.
2016

Congenital diarrhoeal disorders: advances in this evolving web of inherited enteropathies *NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY*
Canani, R. B., Castaldo, G., Bacchetta, R., Martin, M. G., Goulet, O.
2015; 12 (5): 293-302

Forkhead box P3: The Peacekeeper of the Immune System *INTERNATIONAL REVIEWS OF IMMUNOLOGY*
Passerini, L., de Sio, F. R., Roncarolo, M. G., Bacchetta, R.
2014; 33 (2): 129-145

Immunological Outcome in Haploidentical-HSC Transplanted Patients Treated with IL-10-Anergized Donor T Cells. *Frontiers in immunology*
Bacchetta, R., Lucarelli, B., Sartirana, C., Gregori, S., Lupo Stanghellini, M. T., Miqueu, P., Tomiak, S., Hernandez-Fuentes, M., Gianolini, M. E., Greco, R., Bernardi, M., Zappone, E., Rossini, et al
2014; 5: 16-?
- Gene/Cell Therapy Approaches for Immune Dysregulation Polyendocrinopathy Enteropathy X-Linked Syndrome. *CURRENT GENE THERAPY*
  Passerini, L., de Sio, F. R., Porteus, M. H., Bacchetta, R.
  2014; 14 (6): 422-428

- CD4(+) T Cells from IPEX Patients Convert into Functional and Stable Regulatory T Cells by FOXP3 Gene Transfer. *SCIENCE TRANSLATIONAL MEDICINE*
  Passerini, L., Mel, E. R., Sartirana, C., Fousteri, G., Bondanza, A., Naldini, L., Roncarolo, M. G., Bacchetta, R.
  2013; 5 (215)

- Autoantibodies to Harmonin and Villin Are Diagnostic Markers in Children with IPEX Syndrome. *PLOS ONE*
  Lampasona, V., Passerini, L., Barzaghi, F., Lombardoni, C., Bazzigaaluppi, E., Brigatti, C., Bacchetta, R., Bosi, E.
  2013; 8 (11)

- Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. *NATURE MEDICINE*
  Gagliani, N., Magnani, C. F., Huber, S., Gianolini, M. E., Pala, M., Licona-Limon, P., Guo, B., Herbert, D. R., Bulfone, A., Trentini, F., Di Serio, C., Bacchetta, R., Andreani, et al
  2013; 146 (3): 248-261

- Accumulation of peripheral autoreactive B cells in the absence of functional human regulatory T cells. *BLOOD*
  Kinnunen, T., Chamberlain, N., Morbach, H., Choi, J., Kim, S., Craft, J., Mayer, L., Cancrini, C., Passerini, L., Bacchetta, R., Ochs, H. D., Torgerson, T. R., Meffre, et al
  2013; 121 (9): 1595-1603

- Design of experiments as a decision tool for cell therapy manufacturing. *Cytotherapy*
  Lee, E., Shah, D., Porteus, M., Wright, J. F., Bacchetta, R.
  2022

- Alloantigen-specific type 1 regulatory T cells suppress through CTLA-4 and PD-1 pathways and persist long-term in patients. *Science translational medicine*
  Chen, P. P., Cepika, A., Agarwal-Hashmi, R., Saini, G., Uyeda, M. J., Louis, D. M., Cieniewicz, B., Narula, M., Amaya Hernandez, L. C., Harre, N., Xu, L., Thomas, B. C., Ji, et al
  2021; 13 (617): eabf5264

- BHLHE40 Regulates IL-10 and IFN-# Production in T Cells but Does Not Interfere With Human Type 1 Regulatory T Cell Differentiation. *Frontiers in Immunology*
  Uyeda, M. J., Freeborn, R. A., Cieniewicz, B., Romano, R., Chen, P. P., Liu, J. M., Thomas, B., Lee, E., Cepika, A., Bacchetta, R., Roncarolo, M.
  2021

- Co-Expression of FOXP3#1 and FOXP3#2 Isoforms Is Required for Optimal Treg-Like Cell Phenotypes and Suppressive Function. *Frontiers in immunology*
  Sato, Y., Liu, J., Lee, E., Perriman, R., Roncarolo, M. G., Bacchetta, R.
  2021; 12: 752394

- A beta T-Cell/CD19 B-Cell Depleted Haploidentical Stem Cell Transplantation: A New Platform for Curing Rare and Monogenic Disorders
  Bertaina, A., Bacchetta, R., Lewis, D. B., Grimm, P. C., Shah, A. J., Agarwal, R., Concepcion, W., Czechowicz, A., Bhatia, N., Lahiri, P., Weinberg, K. I., Parkman, R., Porteus, et al
  ELSEVIER SCIENCE INC.2020: S288

- Early Epigenetic Immune Quantification Following Alpha/Beta T-Cell/CD19 B-Cell Depleted Haploidentical Stem Cell Transplant Correlates with CD4+ T Cell Recovery at Day+100
  Mayers, M., Schulze, J., Barbarito, G., Lakshmanan, U., Parkman, R., Weinberg, K. I., Chu, J., Agarwal, R., Roncarolo, M., Sachsenmaier, C., Bacchetta, R., Bertaina, A.
  ELSEVIER SCIENCE INC.2020: S305

- Alloantigen-specific Tr1 cells designed to prevent GvHD have a distinct molecular identity and suppress through CTLA-4 and PD-1. *Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting*
Cepika, A., Chen, P. P., Uyeda, M. J., Cieniewicz, B., Narula, M., Amaya, L., Louis, D. M., Xu, L., Ji, X., Bertaina, A., Agarwal-Hashmi, R., Davis, M. M., Meyer, et al. 2020: A159–A159

- Engineered type 1 regulatory T cells designed for clinical use kill primary pediatric acute myeloid leukemia cells. *Haematologica*
  Cieniewicz, B., Uyeda, M. J., Chen, P. P., Sayitoglu, E. C., Liu, J. M., Andolfi, G., Greenthal, K., Bertaina, A., Gregori, S., Bacchetta, R., Lacayo, N. J., Cepika, A., Roncarolo, et al. 2020

- APVO210: A Bispecific Anti-CD86-IL-10 Fusion Protein (ADAPTIR (TM)) to Induce Antigen-Specific T Regulatory Type 1 Cells. *FRONTIERS IN IMMUNOLOGY*
  Pellerin, L., Chen, P., Gregori, S., Hernandez-Hoyos, G., Bacchetta, R., Roncarolo, M. 2018; 9

- CRISPR-Based Therapy for IPEX Syndrome as a Model of Genetic Autoimmunity.
  Goodwin, M., Lee, E., Lakshmanan, U., Shipp, S., Roncarolo, M., Porteus, M., Bacchetta, R. CELL PRESS.2018: 95–96

- Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization. *FRONTIERS IN IMMUNOLOGY*
  Fuchs, A., Gliwinski, M., Grageda, N., Spiering, R., Abbas, A. K., Appel, S., Bacchetta, R., Battaglia, M., Berglund, D., Blazar, B., Bluestone, J. A., Bornhaeuser, M., ten Brinke, et al. 2018; 8: 1844

- Peanut-specific type 1 regulatory T cells induced in vitro from allergic subjects are functionally impaired. *JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY*
  Pellerin, L., Jenks, J., Chinthrajah, S., Dominguez, T., Block, W., Zhou, X., Noshirvan, A., Gregori, S., Roncarolo, M., Nadeau, K., Bacchetta, R. 2018; 141 (1): 202–+

- Identity and Diversity of Human Peripheral Th and T Regulatory Cells Defined by Single-Cell Mass Cytometry. *JOURNAL OF IMMUNOLOGY*
  Kunicki, M. A., Hernandez, L., Davis, K. L., Bacchetta, R., Roncarolo, M. 2018; 200 (1): 336–46

- Hurdles in therapy with regulatory T cells. *Science translational medicine*
  Trzonkowski, P., Bacchetta, R., Battaglia, M., Berglund, D., Bohnenkamp, H. R., Ten brinke, A., Bushell, A., Cools, N., Geissler, E. K., Gregori, S., Marieke van Ham, S., Hilkens, C., Hutchinson, et al. 2015; 7 (304): 304ps18–?

- Hurdles in therapy with regulatory T cells. *Science translational medicine*
  Trzonkowski, P., Bacchetta, R., Battaglia, M., Berglund, D., Bohnenkamp, H. R., Ten brinke, A., Bushell, A., Cools, N., Geissler, E. K., Gregori, S., Marieke van Ham, S., Hilkens, C., Hutchinson, et al. 2015; 7 (304): 304ps18–?

- Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. *Nature biotechnology*
  Hendel, A., Bak, R. O., Clark, J. T., Kennedy, A. B., Ryan, D. E., Roy, S., Steinfeld, I., Lunstad, B. D., Kaiser, R. J., Wilkens, A. B., Bacchetta, R., Tsalenko, A., Dellinger, et al. 2015; 33 (9): 985–989

- Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. *Nature biotechnology*
  Hendel, A., Bak, R. O., Clark, J. T., Kennedy, A. B., Ryan, D. E., Roy, S., Steinfeld, I., Lunstad, B. D., Kaiser, R. J., Wilkens, A. B., Bacchetta, R., Tsalenko, A., Dellinger, et al. 2015; 33 (9): 985–989

- Clinical Features and Follow-Up in Patients with 22q11.2 Deletion Syndrome. *JOURNAL OF PEDIATRICS*
  Cancrini, C., Puliafito, P., Digilio, M. C., Soresina, A., Martino, S., Rondelli, R., Consolini, R., Ruga, E. M., Cardinale, F., Finocchi, A., Romiti, M. L., Martire, B., Bacchetta, et al. 2014; 164 (6): 1475–?

- Identification of STAT5A and STAT5B Target Genes in Human T Cells. *PloS one*
  Kanai, T., Seki, S., Jenkins, J. A., Kohli, A., Kawli, T., Martin, D. P., Snyder, M., Bacchetta, R., Nadeau, K. C. 2014; 9 (1)
• Identification of STAT5A and STAT5B target genes in human T cells. *PloS one*
  Kanai, T., Seki, S., Jenks, J. A., Kohli, A., Kawli, T., Martin, D. P., Snyder, M., Bacchetta, R., Nadeau, K. C.
  2014; 9 (1)

• Tr1 cells and the counter-regulation of immunity: natural mechanisms and therapeutic applications. *Current topics in microbiology and immunology*
  Roncarolo, M. G., Gregori, S., Bacchetta, R., Battaglia, M.
  2014; 380: 39-68

• IL-21 signalling via STAT3 primes human naive B cells to respond to IL-2 to enhance their differentiation into plasmablasts *BLOOD*
  Berglund, L. J., Avery, D. T., Ma, C. S., Moens, L., Deenick, E. K., Bastamante, J., Boisson-Dupuis, S., Wong, M., Adelstein, S., Arkwright, P. D., Bacchetta, R., Bezrodnik, L., Dadi, et al
  2013; 122 (24): 3940-3950

• Combined DOCK8 and CLEC7A mutations causing immunodeficiency in 3 brothers with diarrhea, eczema, and infections *JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY*
  Dinwiddie, D. L., Kingsmore, S. F., Caracciolo, S., Rossi, G., Moratto, D., Mazza, C., Sabelli, C., Bacchetta, R., Passerini, L., Magri, C., Bell, C. J., Miller, N. A., Hateley, et al
  2013; 131 (2): 594-597

• Immunodeficiency with autoimmunity: beyond the paradox. *Frontiers in immunology*
  Bacchetta, R., Notarangelo, L. D.
  2013; 4: 77-?